Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Trial
Official title:
COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study
It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19 with rapid deterioration of respiratory parameters in the last 12 hours.
It is an observational, cohort, retrospective, monocentric, non-profit study. Patients with
SARS-CoV-2 COVID-19 pneumonia who started off-label Ruxolitinib treatment in the period
between 25/03/2020 and 07/04/2020 in hospitalization in the COVID-19 wards of the USL Toscana
Nord Ovest company.
Primary objective
- Evaluation of the efficacy and safety of ruxolitinib in acute respiratory distress syndrome
in patients with SARS-CoV-2 COVID-19 with rapid deterioration of respiratory parameters in
the last 12 hours.
Secondary objectives
- Improvement of respiratory performance.
- Improvement of acute phase inflammation indices.
- Evaluation of known adverse events related to the use of the drug.
- Evaluation of the epidemiological parameters in COVID-19 patients.
- Monitoring of plasma levels of cytokines before and after treatment. Exploratory
objectives
- Analysis of the outcomes for the launch of a study on the efficacy and safety of
Ruxolitinib in the treatment of ADRS in COVID-19 patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05543616 -
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Completed |
NCT04334044 -
Treatment of SARS Caused by COVID-19 With Ruxolitinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Recruiting |
NCT04466241 -
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT04402879 -
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
|
N/A | |
| Recruiting |
NCT04661631 -
Surgery and Lung Ultrasound in COVID-19 Infection
|
||
| Completed |
NCT04376476 -
Host-pathogen Interactions During SARS-CoV-2 Infection
|
N/A | |
| Completed |
NCT04375098 -
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04354779 -
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
|
||
| Recruiting |
NCT04367207 -
African Covid-19 Critical Care Outcomes Study
|
||
| Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Terminated |
NCT04707703 -
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
|
Phase 3 | |
| Active, not recruiting |
NCT04987528 -
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
|
||
| Completed |
NCT04667936 -
Evaluation of Sedation in COVID-19 ARDS
|
||
| Completed |
NCT04423770 -
COVID-19 Related Health and Infection Control Practices Among Dentists
|